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Properdin was originally described by Pillemer and co-workers in 1954 as a 
unique serum protein participating in an alternative pathway of complement 
(C) activation (1). Over the next several years, the sedimentation behavior of 
partially purified preparations of properdin was examined in several laborato- 
ries and values of 27S, 18S, 10S, and 5-7S were variously reported (1-5). Finally, 
in 1968 Pensky and co-workers obtained a homogenous preparation of properdin 
which sedimented at 5.2S in the analytical ultracentrifuge (6). Although earlier 
discrepancies could be attributed at least in part to methodological limitations, 
the possibility could not be excluded that the differences might also have been 
on  a  more substantive  basis,  perhaps  related to  the  degree of purification 
achieved. With the development in our laboratory in 1973 of a radioimmunoas- 
say for the detection of nanogram quantities of properdin (7), sucrose density 
gradient ultracentrifugation  experiments were performed  to determine the sedi- 
mentation behavior of properdin antigen in normal human serum. Radiolabeled 
or  unlabeled properdin purified to homogeneity according to  the  method of 
Pensky et al. (6) served as control. The results, presented in this paper, provide 
evidence for the existence of multiple sedimenting species of properdin antigen 
in serum and identify the third component of C (C3) as a constituent of at least 
one of the heavier sedimenting species. 
Materials and Methods 
Human Serum.  Whole blood was obtained from healthy laboratory volunteers or was pur- 
chased from a  commercial distributor (Knickerbocker Biologicals, Inc., New York), clotted, and 
centrifuged in the cold to separate the serum. Portions were used fresh or stored frozen at -70°C. 
Serum from a patient with partial lipodystrophy was supplied by Dr. Robert McLean, University 
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of Connecticut Health Center, Farmington, Conn. Serum from a  patient genetically deficient in 
C3 was supplied by Doctors Chester Alper and Fred Rosen, Children's Hospital Medical Center, 
Boston, Mass. 
Human Plasma.  Blood from healthy donors (7 ml) was drawn into glass vacutainers contain- 
ing  70  t~l of 15%  K3EDTA  solution  (3204  QS;  Becton,  Dickinson  &  Co.,  Orangeburg,  N.  Y.). 
Centrifugation at 3,000 rpm  and 10,000 rpm sequentially separated cells and platelets,  respec- 
tively, from plasma. 
Buffers.  Phosphate-buffered saline (PBS), 1 pH  7.4,  ionic strength 0.15  tL,  was used as is or 
fortified with 5  x  10  -3 M EDTA by diluting with a  stock solution of 0.15 M EDTA,  pH 7.4.  PBS, 
ionic  strength 0.075  tL was  made  by diluting  PBS  (vol/vol) with deionized  water;  PBS,  ionic 
strength 0.45 tL was made from 10 times stock solution of PBS. Where indicated, divalent metal 
cations Ca  2+ and Mg  2+ were present at 1.5 x  10 -4 M and 5  x  10 -4 M, respectively. 
Antisera.  Rabbit antisera to human C3, properdin, and factor B were prepared with purified 
antigens after a general immunization regimen described elsewhere (7). When necessary, antisera 
were rendered monospecific by immunoabsorption with human gamma globulin (American Cy- 
anamid Co., Lederle Laboratories, Pearl River, N. Y.). Native or absorbed antisera were stored at 
-20°C.  Goat antiserum to whole human serum was purchased (Meloy Laboratories, Inc., Spring- 
field, Va.). 
Purified Proteins.  Human activated praperdin (P) was purified from pooled normal serum by 
the zymosan adsorption andcolumn chromatographic method described by Pensky et al. (6). 
Human C3 was prepared by modification (8) of the method of Nilsson and Mfiller-Eberhard (9). 
Human C3b was generated by incubating purified C3 with serum-exposed washed cobra venom 
factor  (CVF)  sepharose  beads  (10).  Low  molecular  weight  by-products  of the  reaction  were 
separated from C3b by chromatographing on a calibrated Sephadex G-200 column. C3b eluted in a 
homogeneous peak at a  position corresponding to a  mol wt of 162,000  daltons. 
Human C3c was prepared according to the protocol for the purification of C3 with the following 
changes. To generate C3c in serum, the alternative pathway of C was activated by pretreating the 
starting serum  with zymosan (4  mg/ml,  lot no.  7B-340,  Fleishchmann Laboratories,  Standard 
Brands, Inc., New York) at 37°C for 20 min. Du~ing the zymosan activation step no precautions 
were  taken  to  inhibit  C3b  inactivator.  The  first  column  chromatographic  step  (DEAE)  was 
conducted using buffer 10 times more concentrated in EDTA than indicated in the protocol (8,9). 
C3c eluted on the descending side of the dropthrough peak and was recycled on the same column 
before proceeding to the second column step. The mol wt of purified C3c was 110,000 daltons (10) as 
determined by analytical sodium dodecyl sulfate disc gel electrophoresis (kindly done by Ronald J. 
Field, Children's Hospital Medical Center, Boston, Mass.). Human Factor B (C3 proactivator) was 
purified as described previously (11). 
CVF was isolated from crude cobra venom (lyophilized, Naja naja, Venom Laboratory, Silver 
Springs,  Fla.)  by DEAE-cellulose  chromatography  (microgranular,  DE52,  Whatman;  H  Reeve 
Angel  &  Co.,  Clifton,  N.  J.).  CVF  eluted  in  a  linear salt  gradient;  the  starting buffer  was 
phosphate buffer, pH 7.3,  1.9mS (23°C) fortified with chloramphenicol 5  x  10 .5 M  and the limit 
buffer was 0.5 M NaC1 in starting buffer. Fractions containing CVF were identified by screening 
for anticomplementary activity using a modification of the method of Ballow and Cochrane (12). 
Concentration of Protein Solutions.  This was  accomplished on Amicon PM10 ultrafiltration 
membranes (Diaflo; Amicon Corp.,  Scientific Sys. Div., Lexington, Mass.) in pressurized (40-70 
lblin  2 nitrogen), stirred cells at cold room temperatures. 
Solid-Phase CVF.  Covalent linkage of CVF to sepharose 4B (CNBr activated; Pharmacia Fine 
Chemicals, Inc., Uppsala, Sweden) was accomplished by mixing 10 mg CVF with 2 g swollen beads 
in 0.1 M borate buffer, pH 8.6, containing 0.5 M NaC1. The slurry was incubated for 2 h  at room 
temperature and overnight at 4°C.  Free CNBr sites were blocked with 1 M ethanolamine, pH 8.0. 
Nonspecifically absorbed protein was removed by sequential washes with 0.1 M acetate buffer, pH 
4, containing 1 M NaC1 and 0.1 M borate buffer, pH 8.6, containing i M NaC1. Sepharose-CVF was 
suspended in PBS for use. 
i Abbreviations used in this paper: BGG, bovine gamma globulin; BSA, bovine serum albumin; 
CVF, cobra venom factor; CTY C, cytochrome C; P, human activated properdin; PBS, phosphate- 
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Molecular Weight Markers.  Substances used to calibrate Sephadex G-200 columns were Blue 
Dextran  (2000,  Pharmacia  Fine  Chemicals,  Inc.,  Piscataway,  N.  J.),  bovine gamma  globulin 
(BGG) (160,000 daltons, Fraction II, bovine plasma; Armour Laboratories, Armour and Company, 
Chicago, Ill.), bovine serum albumin (BSA) (69,000 daltons, Fraction V powder, Sigma Chemical 
Company, St. Louis, Mo.), and cytochrome C (CYT C) (12,500 daltons, horse heart, Schwarz/Mann 
Div., Becton, Dickinson & Co., Orangeburg,  N.  Y.).  Sedimentation positions in sucrose density 
gradients were marked with thyroglobulin (19.2S) (porcine, Type II, Sigma Chemical Company), 
BGG (7.3S), BSA (4.5S),  ovalbumin (3.5S) (2×  Cryst,  Schwarz/Mann Div.,  Becton, Dickinson & 
Co.), and CYT C (1.5S). Radiolabeled or unlabeled human properdin sedimented at approximately 
6S under the conditions employed for sucrose density gradient ultracentrifugation. 
Solid-Phase Radioimmunoassay for Human Properdin.  This was performed by major modifica- 
tions of a  published method (7). Two variations of the solid-phase radioimmunoassay were used, 
the sequential technique and the equilibrium technique. In view of the central importance of these 
assays in the experiments to be described, the precedures and data analyses are described in some 
detail. 
Polystyrene tubes (12  ×  75 mm, Falcon Plastics, Div. of BioQuest, Oxnard, Calif.) were coated 
at  room  temperature  for  2  h  with  1  ml  of diluted  monospecific  rabbit  antiserum  to  human 
properdin (1:1,000 in 0.06 M  sodium barbital buffer, pH 9.6).  Unbound antibody was aspirated. 
According  to  schedules  that  will  be  delineated,  the  tubes  were  filled  with  solutions  (1  ml) 
containing unlabeled properdin (unknown sample), radiolabeled iodine-125 properdin (1~51-15), or a 
mixture of both. PBS buffer fortified with 1% BSA and 0.02% sodium azide served as diluent. For 
the equilibrium radioimmunoassay,  solutions of unlabeled properdin (sample)  and a  standard 
concentration of 1251-15 {10-20 ng 15/ml,  -800-1800 cpm/ml) were mixed, transferred to antibody- 
coated tubes, and incubated; for the sequential radioimmunoassay the tubes were filled first with 
sample and incubated, then aspirated, and then refilled with the standard concentration of 125I-P 
and reincubated. Various dilutions of a  control serum pool, assumed to contain a  normal serum 
concentration of properdin (25 ~g 15/ml), were included in selected assays to serve as a  reference 
curve  with  which to  compare  samples.  Equilibrium  conditions between  antibody irreversibly 
bound to the tube wall and antigen were established after incubation overnight (16-24 h) in a 
temperature-controlled  (37°C  _+  1°C),  humidified incubator  (Double chamber incubator,  Model 
17060-00Z,  National Appliance Co., Portland, Ore.). Additional tubes that held only the standard 
concentration of  125I-P were  placed  directly  into plastic carrier tubes  and counted  10 min for 
gamma  emission;  the  average  total  count  (T)  was  expressed  in  counts  per  minute.  For  all 
remaining tubes, including several that contained only ~251-15, the free antigen was separated from 
the bound antigen by aspirating and discarding the liquid contents (free antigen) before counting 
the tubes. For each tube that had contained sample antigen the corresponding counts per minute 
were designated bound counts (B). The average counts per minute of the tubes that had contained 
only ~2sI-15 at the standard concentration was referred to as maximum bound counts (Bo). In all of 
the assays reported in this paper, the ratio Bo/T  ×  100 was between 68-100%. 
In some experiments the amount of properdin in samples was expressed simply as the percent 
ratio B/T  symbolized B/T-%  (B/T  ×  100).  A  plot  of the  logarithm  of the  microliters of the 
properdin-containing serum or of the nanograms of P  against the arithmetic values of B/T-% 
gave a sigmoidal function. Over a considerable range of this curve, the values plotted as a straight 
line with slope m. The ratio of potencies between two properdin-containing solutions, one giving a 
value  of  BI/T-%  and  the  other  B2/T-%,  was  then  equal  to  the  antilog  {[(B~/T-%)  - 
(B2/T-%)]/m}. In a limited number of experiments all B/T-% values were related toBo]T-%, the 
maximum uptake value, by the formula, antilog {[(Bo/T-%) -  (B/T-%)]/m}, and the data were 
recorded  as  relative  concentration  of properdin.  In  assays  that  included  both  experimental 
samples and dilutions of the control serum,  it was possible to report the data as nanograms of 
properdin. In these cases, a logit transformation was employed. The B values corresponding to the 
dilutions of the control sera were first converted to Y values by the formula Y  = B/Bo and then Y 
values were converted to logit values Y/1 -  Y. The points (nanograms P, Y/1 -  Y) when plotted on 
2-cycle log-log scale yielded a set of points through which a straight line could be interpolated. The 
equation of the straight line permitted the calculation of nanograms of properdin (ng P) for each 
Y/1 -  Y  value representing experimental samples. To facilitate the calculations a programmable 
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For each freshly labeled batch of 125I-I~, the standard concentration of properdin was determined 
from a standard curve.  1-ml vol of increasing concentrations of 125I-1~ were incubated under assay 
conditions in antibody-coated tubes.  Tubes were  counted for gamma  emission for  10 min (T), 
aspirated,  and the emptied tubes were recounted (B). The resultant standard curve of B  vs. T 
plotted  on  log-log scale  progressed  from  a  linear curve  at  lower  concentrations of ~25I-1~ to  a 
hyperbolic curve at higher concentrations of ~5I-1~. The T value of the point of transition from the 
linear to the hyperbolic region on the standard curve was taken to be the standard concentration of 
1251.1~" 
Radioiodination ofProperdin.  Purified properdin was labeled with ~25I according to the iodine 
monochloride method of Helmkamp  et  al.  (13).  The  radiolabeled protein was buffered in PBS 
containing 0.5% BSA, starilely filtered (0.45  pm disposable filter unit, Millipore Corp., Bedford, 
Mass.) and stored at refrigerator temperatures (+4-8°C). 
Measurement of Radioactivity.  Polystyrene  assay tubes or glass  tubes  (12  x  75 ram) were 
placed into 16  ×  125 mm plastic carrier tubes (Amersham/Searle Corp., Arlington Heights, Ill.) 
and counted for gamma radiation at optimal instrument settings in a  scintillation well counter 
(Model 4230, Nuclear-Chicago Corporation, Des Plaines, Ill.). 
Sucrose Density Gradient Ultracentrifugation.  Density gradient ultracentrifugation was per- 
formed by a  modification of the method of Martin and Ames (14),  described by Pensky et al. (6), 
~employing an L2-65B Model Ultracentrifuge and SW 41 rotor (Beckman Instruments, Inc., Spinco 
Div., Palo Alto, Calif.). Gradient fractions containing marker proteins were diluted with 0.3 ml of 
PBS and measured for protein concentration at OD  280  nm in a  1 cm  path  in a  Zeiss PMQ.II 
Spectrophotometer (Carl Zeiss, Inc., New York). Portions of gradient fractions containing serum 
or purified C proteins were analyzed for protein by the Folin method (15). 
Hemolytic assay for C3.  The relative concentration of C3 in fractionated serum was assayed 
using the intermediate complex EAC4, prepared by modification of the method of Borsos and Rapp 
(16),  and  KBr-treated  serum  as  a  reagent  lacking  C3  and  C4  (17,18).  This  modification was 
developed  by  Mr.  Ira  Goodkofsky  in  our  laboratory.  Veronal-buffered  saline,  pH  7.4,  ionic 
strength 0.15 ~,  containing 1.5  ×  10 -4 M  Ca 2+, 5  x  10 -4 M  Mg  2+, and 0.05% gelatin served as 
diluent and was prepared as described elsewhere (19).  Reaction mixtures containing 0.1 ml of 
EAC4 (3.3  x  10S/ml),  0.2 ml of KBr-treated serum diluted 1/25,  and 0.2 ml of serial dilutions of 
sample were incubated at 37°C for 30 rain. After the addition of 2 ml of chilled buffer, the tubes 
were centrifuged and the supernatant fluids read at 415 nm to measure hemolysis. The reciprocal 
of the dilution of sample that resulted in 50% hemolysis was taken as the relative concentration of 
C3. 
Results 
Observation of Multiple Sedimenting Species of  Properdin in Human Serum 
and Plasma.  As shown in Fig. 1, properdin antigen in normal serum subjected 
to sucrose density gradient ultracentrifugal analysis separated into one peak 
and two shoulders with approximate sedimentation coefficients of 6S, 9S, and 
12S. For comparison, purified 125I-P sedimented homogeneously at about 6S,  a 
finding in  accord with  previously published  reports  (6,20).  The  total  serum 
proteins were resolved as expected into 4S, 7S, and 19S peaks. The distribution 
of properdin in the 6S, 9S, and 12S species in serum under these conditions was 
8, 36, and 56%, respectively, as estimated by integration of the area under each 
peak after the logarithmic ordinate of Fig. i was converted to a linear scale. 
To  exclude the  possibility  that  multiple  sedimenting species of properdin 
constituted an isolated finding unique to  a  single serum,  sera from several 
different donors were analyzed under similar experimental conditions. Essen- 
tially indistinguishable results were obtained. Furthermore, no difference oc- 
curred when the gradients were made in PBS without added Mg  2÷ or when the 
analyzed samples  were fresh  serum,  serum that  had been  stored frozed at 
-70°C, or serum that had been dialyzed against PBS. JANE  CHAPITIS  AND  IRWIN  H.  LEPOW  245 
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FIG.  1.  Properdin antigen in normal human serum (NHS) compared with purified 12~I-1~. 
NHS (0.5 ml) and 1251-15 (4 ~g/ml) were layered on 10-40% linear sucrose density gradients 
made in  PBS  containing 5  x  10-'  M  big  2+,  and were separated by ultracentrifugation 
40,000 rpm, 2°C, 29 h). Thyroglobulin (19.2S)  and ovalbumin (3.5S)  served as markers. 
The phenomonon was not an effect secondary to blood coagulation nor was it 
influenced by chelation of divalent cations since the properdin antigen profiles 
were  similar  in  EDTA  plasma  and  serum.  Concentrating  serum  twofold by 
Amicon ultrafiltration  and layering increasing volumes of either concentrated 
or  native  serum  onto  gradients  failed  to  alter  the  distribution  of properdin 
antigen  originally  observed when  0.5 ml  of native  serum  was  applied to the 
gradient. 
In these and in subsequent gradient experiments to be described, no properdin 
antigen in serum was ever detected at positions lighter than 6S. This serves as 
presumptive evidence that  -6S properdin  antigen  in serum  and  -6S highly 
purified properdin are similar molecular entities.  Heavier sedimenting species 
of properdin  antigen  in serum,  amounting  to approximately  90% of the total 
properdin in serum, might, therefore, represent polymers of properdin, protein 
complexes between properdin and other serum proteins, or conceivably, a combi- 
nation of polymerization and protein complex formation. Accordingly, the effect 246  MULTIPLE  SEDIMENTING  SPECIES  OF  PROPERDIN 
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FIa.  2.  Effect of dilution of serum on the sedimentation of properdin antigen. Equal vol 
(0.5  ml)  of serum  samples were  layered onto  10-40~  sucrose gradients  made  in  PBS. 
Ultracentrifugation at 37,000 rpm was conducted at 2°C for 28 h. The positions ( ~ ) of  C3 and 
~251-15 were obtained from another gradient experiment run under identical conditions. 
of several parameters known to influence protein-protein interactions was inves- 
tigated. 
Effect of  Dilution, Ionic Strength, and Temperature on the Multiple Sediment- 
ing Species of  Properdin in Serum.  Dilution of serum by as little as 1/2.5 with 
PBS buffer fortified with 0.5% BSA before sucrose gradient fractionation occas- 
sioned loss of 12S properdin and a concomitant increase in concentration of both 
9S and 6S properdin.  As shown in Fig. 2, the effect was reversible. Serum that 
had  been diluted  1/5  with  PBS was subsequently reconcentrated  to  1/1.33  by 
Amicon ultrafiltration.  The relative concentration of 6S, 9S, and 12S properdin 
in  reconcentrated  serum  assumed  proportions  similar  to  those  seen  in  the 
original serum. 
Dialysis of serum against pH 7.4 PBS of ionic strengths 0.075, 0.15, and 0.45/~ 
was without effect on the distribution  of total  serum proteins  in sucrose gra- 
dients (right-hand panel of Fig. 3). However, profound effects were apparent on 
the various sedimenting species of properdin antigen (left-hand panel of Fig. 3); 
lower ionic strengths induced heavier sedimenting species of properdin antigen 
while higher  ionic strengths  favored lighter  sedimenting  species of properdin 
antigen. In this experiment fewer gradient fractions were subjected to radioim- 
munoassay,  resulting  in  poorer  resolution  of properdin  species  in  Fig.  3  as 
compared  with  Fig.  1.  Nevertheless,  at  physiologic ionic  strength  of 0.15  /~, 
properdin  antigen  appeared to be distributed  as  -6S,  9S,  and  12S species.  A JANE  CHAPITIS  AND  IRWIN  H.  LEPOW  247 
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FIC.  3.  Effect of serum iomc strength on the sedimentation of properdin antigen.  Serum 
(0.5 ml) in pH 7.4 PBS of ionic strengths 0.075,  0.15,  and 0.45 /~ were centrifuged (37,000 
rpm,  2°C,  29 h) on 10-40% gradients made in the respective buffers. Indicated sedimen- 
tation positions ( ~ ) were interpolated from a  standard sedimentation coefficient line ob- 
tained from a  previous experimental run conducted under identical conditions. 
threefold increase in ionic strength resulted in reduction in concentration of 12S 
properdin and an increase in both 6S and 9S properdin. Conversely, reducing the 
ionic strength to one-half physiologic ionic strength effected a  disappearance of 
6S and 9S properdin, reduction of 12S properdin and the appearance of a heavier 
species of properdin antigen sedimenting at  -15S. 
In order to investigate the effect of temperature on the distribution of proper- 
din antigen in human serum, 0.5 ml of serum was layered on a  10-40% linear 
sucrose gradient in PBS (pH 7.4;/~, 0.15) and centrifuged at 41,000 rpm for 26 h 
at  23°C.  Under  these  conditions  properdin  was found only in  the  6S and  9S 
positions, suggesting that dissociation of the 12S peak had occurred. 
As shown by the effects of varying serum concentration,  ionic strength,  and 
temperature,  the  sedimentation  behavior  of properdin  antigen  in  serum  dis- 
played characteristics of protein-protein disseciation-association reactions. The 
evidence supported the concept that properdin in serum exists as multimolecu- 
lar  complexes.  The  nature  of the  protein  or  proteins  with  which  properdin 
interacts was therefore next investigated. 
Sedimentation  of Properdin  Antigen  in Serum from Patients  with Genetic 
Deficiency of C3 and with Partial Lipodystrophy.  Among the hypotheses that 
could explain the observations in the preceding sections was the possibility that 
properdin forms multimolecular complexes with other constituents of the alter- 
native  pathway.  It  was  therefore  of interest  to  examine  the  distribution  of 
properdin  antigen  in  sera  from  patients  with  two kinds  of C3  abnormality. 
Indeed,  as compared with  normal  serum,  there was marked difference in the 
sedimentation of properdin in serum genetically lacking C3 (21) (Fig.  4). This 248  MULTIPLE  SEDIMENTING  SPECIES  OF  PROPERDIN 
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FIG.  4.  The sedimentation ofproperdin antigen in genetically C3-deficient serum. Geneti- 
cally C3-deficient serum (0.5 ml) and normal human serum (NHS) (0.5 ml) were centrifuged 
(37,000 rpm, 2°C, 28 h) on 10-40% gradients made in PBS. The positions ( ~ ) of C3 and l~sI-t~ 
were obtained from another gradient experiment run under identical conditions. 
serum is totally deficient in C3 but contains other known constituents of the 
alternative pathway. Properdin sedimented in a broad peak at approximately 
7S,  a  position intermediate between normally present 6S  and 9S  properdin. 
Furthermore, when partial lipodystrophy serum, which contained C3 nephritic 
factor and lacked detectable C3 antigen (less than 3% normal C3 concentration), 
was fractionated on sucrose gradients, properdin antigen again sedimented at 
predominantly -7S (left-hand panel of Fig.  5).  The patient's serum showed a 
relatively normal total protein distribution (right-hand panel of Fig.  5).  For 
comparison, normal human serum again contained -6S, 9S, and 12S properdin. 
It therefore appeared that C3 might be a protein with which properdin interacts 
and the experimental approach was shifted to examination of the sedimentation 
properties of purified properdin in the presence or absence of purified C3. 
Sedimentation  of Puri~ed Properdin Alone or in  the Presence of Various 
Concentrations  of Purified C3,  C3b,  or C3c.  Sucrose gradient fractionation 
was utilized to study the role of C3 and two catabolic products of C3, C3b and 
C3c, on the sedimentation of purified properdin. Chilled solutions of the appro- 
priate purified proteins were mixed at cold room temperatures (4-8°C) and the 
resultant mixtures were applied directly to cooled gradients just before centrifu- 
gation. As shown in the left-hand panels of Figs.  6-8,  in the three mixtures 
containing the highest molar ratios of C3, C3b, or C3c to properdin (29.1/1), that A 
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FIG.  5.  The sedimentation of properdin antigen in partial lipodystrophy serum.  Partial 
lipodystrophy serum (PLD) (0.5 ml) and normal human serum (NHS) (0.5 ml) were centri- 
fuged  (41,000  rpm,  2°C,  26 h) on  10-40% gradients made  in PBS.  Thyroglobulin,  BGG, 
ovalbumin, and 1251-15 served as markers ($). 
is, at ratios lower than but approaching concentrations existing in native serum, 
purified properdin shifted from its -6S position to heavier gradient positions. At 
the highest ratios of C3 or C3b to properdin (left-hand panels of Figs. 6 and 7, 
respectively), properdin localized in the same position occupied by the respective 
homogeneous protein peaks, corresponding to values of -9S and  -8.7S (right- 
hand panels of Figs. 6 and 7, respectively). However, at the highest ratio of C3c 
to properdin, properdin sedimented at  -8.2S,  a  position in the gradient that 
corresponded to the region of asymmetry on the heavier side of the respective 
protein curve (right-hand panel of Fig. 8). At lower molar ratios of C3, C3b, or 
C3c to properdin (11.6/1, 5.8/1, and 2.9/1) distinct peaks of properdin sedimented 
with coefficients intermediate between expected values. The expected heavier 
value was previously defined by the position of properdin in mixture with the 
highest molar ratio of C3, C3b, or C3c to properdin (29.1/1),  and the expected 
light value at approximately 6S, the control position of purified properdin alone. 
The possibility that  the intermediate sedimentation values could have been 
ascribed to artifactual error was ruled out. Total protein analysis of the gra- 
dients which monitored only the  C3  species of protein in  the mixtures (the 
smaller quantities of properdin were below the level of detection of the assay) 
showed that in all mixtures (right-hand panel of Figs. 6-8) the positions of the 
protein peaks varied only within the limits of experimental error.  Therefore, 
technical aberrations introduced into the gradients could not serve as the basis 
for  a simple explanation of  the  intermediate sedimenting species  of  properdin. A 
theoretical  basis for  the observed complex sedimentation pattern of  properdin in MOLAR  RATIO  C3/P 
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Fro.  6.  The sedimentation of purified properdin in the presence or  absence of various 
concentrations  of purified  C3.  Equal  vol  (0.5  ml)  of properdin  (control)  or  mixtures  of 
properdin and C3 were centrifuged (41,000 rpm, 2°C, 17 h) on 1-15% gradients made in PBS. 
BGG, BSA and CYT C served as markers ( ~ ). 
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FIG.  7.  The sedimentation of purified properdin in the presence or  absence of various 
concentrations of purified  C3b.  Equal  vol  (0.5  ml) of properdin  (control) or  mixtures of 
properdin and C3b were centrifuged (41,000 rpm,  2°C,  15 h) on 1-15% gradients made in 
PBS. BGG, BSA, and CYT C served as markers (  ~  ). 
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Fro.  8.  The sedimentation of purified properdin in the presence or  absence of various 
concentrations of purified  C3c.  Equal  vol  (0.5  ml) of properdin (control) or  mixtures of 
properdin and C3c were centrifuged (41,000 rpm,  2°C,  17 h) on 1-15% gradients made in 
PBS. BGG, BSA, and CYT C served as markers ( ~ ). 
these experiments  is suggested by the work of Cox (22) and will be discussed 
below. 
A  comparison  of the  molar  ratios  at which  heavier  sedimenting  species of 
properdin were lost constituted one criterion to estimate the hierarchy of affinity 
constants between properdin and C3, C3b, and C3c. By this criterion, properdin 
demonstrated the strongest affinity for C3c; C3b was bound by properdin with 
slightly more affinity than was C3. 
Sedimentation of Properdin in the Presence of C3 and Factor B.  Although 
the data of the previous section clearly indicated that properdin interacts with 
C3 or C3 products,  the more complex sedimentation behavior of properdin  in 
normal  human  serum  (Fig.  1)  was  not  reproduced  under  the  experimental 
conditions employed. It was recognized that  more extensive experiments  as a 
function  of concentration  of reactants  and  physicochemical  parameters  were 
required  before any firm  conclusion  could be drawn  concerning  the  possible 
participation  of proteins other than properdin  and  C3 in species of properdin 
antigen heavier than 9S. Nevertheless it was of interest to examine the effect of 
factor B, a readily available purified protein of the alternative pathway, on the 
sedimentation of purified properdin and C3. In fact, as shown in Fig. 9, factor B 
was entirely without influence on the sedimentation of properdin-C3 mixtures, 
even  though  the  concentration  of factor  B  was  at  physiological  level.  This 
experiment also provided evidence that the interaction ofproperdin with C3 was 
not a  general property of proteins other than  C3. This conclusion is apparent 252  MULTIPLE  SEDIMENTING  SPECIES  OF  PROPERDIN 
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FIG.  9.  Sedimentation of purified properdin alone or in the presence of factor B, C3, or 
factor  B  and  C3.  Equal  vol  of the  indicated  purified  protein  solutions  (0.5  ml)  were 
centrifuged (41,000 rpm,  2°C,  17.5 h) on 1-15% gradients made in PBS.  BGG, BSA,  and 
CYT C served as markers (  ~  ). 
from the  data in  Figs.  4  and 5  with  C3-deficient human sera  and from our 
observation that the sedimentation behavior of purified properdin was unaf- 
fected by the presence of high concentrations of BSA. 
Discussion 
Utilizing linear sucrose density gradient ultracentrifugation as an analytical 
tool, this paper has shown that "native" properdin (P) in either serum or plasma 
was  separated  into  multiple  sedimenting  species  (Fig.  1).  For  comparison, 
highly purified "activated" properdin (15) sedimented as a  single homogenous 
protein  peak  at  -6S.  Throughout the  course of these  studies  no  properdin 
antigen was detected with sedimentation coefficients less than -6S. Employing 
conditions of low ionic strength (0.075 g) and cold temperature (2°C) species of 
properdin with Svedberg rates as high as 15S were found (Fig. 3). The experimen- 
tal results may serve to explain, at least in part, the wide range of sedimenta- 
tion rates (27S-5S) that have been earlier reported for partially purified prepara- 
tions ofproperdin (1-5). These preparations ofproperdin, probably containing 15, 
may have been contaminated, for example, with sufficiently high concentra- 
tions of C3 or C3-degradative products to the extent that variable amounts of 
heavier sedimenting protein-protein complexes of C3 contaminants and proper- 
din were present. Purified 15 complexed with purified C3, C3b, or C3c (Figs. 6-8). 
It is of interest that Minta (23) has reported that 15 added to normal serum or to 
serum rendered deficient in properdin sedimented heavier in sucrose gradients. 
He attributed the finding to aggregation of 15 or to complex formation of 15 with a JANE  CHAPITIS  AND  IRWIN  H.  LEPOW  253 
serum euglobulin (probably C3) mediated by an as yet incompletely character- 
ized serum factor, factor F. 
With dilution, the sedimentation of properdin in serum was altered by a shift 
toward lighter sedimenting  species and the effect  was reversed after reconcentra- 
tion (Fig.  2). Previously it had been realized that the functional activity of the 
alternative pathway markedly decreased with dilution (1). Perhaps interaction 
of properdin with complexing proteins,  of which at  least one is  native C3, 
constitutes a critical factor for the functional initiation and/or activity of proper- 
din. Technically  limited by the sample density that can be layered onto a sucrose 
gradient and the limitations of concentrating serum, heavier species of proper- 
din were not demonstrated in concentrated serum relative to unconcentrated 
serum. 
Increasing temperature from 2 to 23°C effected a shift of properdin to lighter 
species. It was not ascertained whether during the long gradient run at warm 
temperature the alternative pathway may have been activated, thereby account- 
ing for the results obtained. It is important to emphasize that present data are 
not sufficient to describe the actual state of association of native properdin with 
other serum proteins in vivo nor to relate such associations to the functional 
activity of properdin in the alternative pathway. 
Purified 15 mixed with purified C3 or C3 catabolic products sedimented in 
complex patterns that were dependent on the molar ratio of C3, C3b, or C3c to 
properdin (Figs.  6-8).  Properdin-containing complexes exhibited the highest 
sedimentation coefficients at the highest molar ratio examined. Reduction of the 
molar ratio resulted in properdin species with smaller sedimentation coeffi- 
cients; the smallest values were only slightly larger than control properdin. In 
some mixtures distinctly bimodal peaks sedimented intermediate between the 
heaviest and lighest properdin species.  A plausible theoretical basis for these 
results is derived from the work of Cox which describes ~the sedimentation and 
diffusion of macromolecular  solutes that undergo rapidly re-equilibrating associ- 
ation-dissociation reactions of the type nA~.~An"  (22). The sedimentation pattern 
generated is dependent on a variety of physicochemical parameters, including 
initial solute concentration and affinity constant, which dynamically influence 
the state of equilibrium of the system in an ultracentrifugal field. Asia result, 
multiple boundaries or single boundaries of various shapes and at different 
positions arise. Although it is recognized that Cox's data relate to homogenous 
solute systems (22,24,25) they may nevertheless provide conceptual insight into 
the heterogeneous solute systems described in this paper (15 and C3, 15 and C3b, 
or 15 and C3c). 
Experiments are in progress that are aimed at distinguishing the possibilities 
that multiple sedimenting species of native properdin in serum are composed 
solely of properdin and C3 or whether additional serum factors are involved. 
Initial efforts are being made to pursue the studies already begun by incorporat- 
ing into mixtures higher concentrations of purified 15 and C3  under various 
physicochemical  conditions in an attempt to generate species of properdin heav- 
ier than the 9S complexes shown in Figs. 6 and 9. In addition mixtures of  various 
combinations  and  concentrations of properdin,  C3,  factor  B,  and  factor I3, 
another component of the alternative pathway, are being examined. In experi- 254  MULTIPLE  SEDIMENTING  SPECIES  OF  PROPERDIN 
ments already completed, the presence of factor B in mixtures of purified 15 and 
C3  or  15  alone  was  without  effect on  the  sedimentation  of 15  (Fig.  9).  In  a 
preliminary experiment,  the further addition of -8,000 U  of purified factor I) 
(kindly  supplied  by  Dr.  Douglas  T.  Fearon,  Robert  B.  Brigham  Hospital, 
Boston, Mass.) to mixtures of 15, C3, and factor B at the concentrations shown in 
Fig. 9 resulted in appearance of a shoulder on the descending side of the 9S peak, 
corresponding  to  -llS.  Although  this  observation requires  confirmation  and 
extension,  it suggests that  complexes of properdin  sedimenting  more rapidly 
than 9S  may  in  fact  involve  the  further  participation  of constituents  of the 
alternative pathway in addition to C3. In further experiments, one would choose 
ideally to study native or precursor proteins (26,27). 
Macromolecular complexes of proteins are a recurrent finding in the classical 
C  pathway.  Protein-protein  interactions  characterize  precursor  molecules  as 
well as molecules that  subsequently become activated (28-36).  Despite a  less 
well-characterized sequence of reactions,  several lines of evidence indicate that 
multimolecular complexes also assemble on the particulate surfaces of initiating 
agents of the  alternative  pathway.  First,  the cellular intermediate  EAC4,3,P 
was  shown  to  be  10-  to  20-fold  more  susceptible  to  lysis  compared  with  an 
analogous intermediate lacking properdin (37). For lysis the intermediates were 
incubated  in  the  presence  of factor  B,  factor  I),  and  a  source  of C3-9.  The 
presence  of properdin  in  EAC4,3,P,B  probably  stabilized  the  C3-convertase 
C3-b--,B,B. Second, the zymosan intermediate ZX  d2 contained C3b which provided a 
site  for  further  interaction  with  factor  B,  thereby  forming  ZXd~C3b,B  (38). 
Circumstantial  evidence  supported  the  existence  of  the  intermediate 
ZXd2C3b,P,B. Third,  it has been shown that binding of radiolabeled 15 to zymo- 
san required the presence of functionally active C3 (factor A) and factor B (39). 
Further, it was demonstrated that the washed intermediate complex ZX which 
was initially formed by incubating Z with serum was able to bind radiolabeled 
15.  Fourth,  in a  system utilizing  agar gels as initiating  agent,  visible protein 
zones containing properdin  and C3 but not factor B were formed after double 
diffusion of normal human serum and purified properdin. Factor B was required 
for the reaction (40). Finally,  highly pertinent  data were published while this 
paper was in final stages of preparation. Agglutination of the cellular intermedi- 
ate EAC4,--3 by 15 was described in a reaction that was dependent on C3 but not 
C4  and  which  was  competitively  inhibited  by  soluble  C3  or  C3b.  Further, 
formation of functionally active 15-C3 convertase, a  C3-convertase, required~15, 
native C3, factors B  and I),  and magnesium  ions (41).  Thus,  multiple lines of 
evidence indicate that properdin complexes with other proteins of the alterna- 
tive  pathway  but  our  communication  is  the  first  to  our  knowledge  which 
demonstrates by physicochemical criteria the direct interaction of properdin and 
C3. 
Complexes or aggregates of alternative pathway proteins in tissues, such as 
are demonstrated  using immunofluorescent  techniques,  may occur by mecha- 
nisms other than active deposition via the alternative pathwaY sequence.  We 
have demonstrated  that purified 15 complexes with purified  C3,  C3b, and C3c 
and that the affinity of 15 for C3c may be higher than for C3 or C3b (Figs. 6-8). 
Consequently, properdin that is found deposited in tissue sections may, in fact, JANE  CHAPITIS  AND  IRWIN  H.  LEPOW  255 
be  bound to  C3b  or  C3c  once these  species  are  formed pari pa~su  with  the 
operation of other C-activating mechanisms. The finding of properdin deposits 
in various pathological situations should therefore not be interpreted as firm 
evidence for an  initiating role for the alternative pathway in the absence of 
other supporting data. 
Summary 
Normal  human  serum  subjected  to  sucrose  density  gradient  analysis  ex- 
hibited multiple sedimenting species of properdin antigen.  Properdin antigen 
distribution was dependent on serum concentration, ionic strength, tempera- 
ture, and the presence of C3, and was not dependent on the presence of divalent 
metal cations or blood coagulation. In mixtures of purified components, proper- 
din sedimented heavier in the presence of C3, C3b, or C3c. Addition of  facter B to 
mixtures containing C3 and properdin was without effect. These data provide 
insights  into earlier discrepancies concerning the  sedimentation behavior of 
partially purified properdin, indicate a  propensity of some constituents of the 
alternative pathway to form protein-protein complexes, and suggest caution in 
interpretation of immunopathological studies in which properdin deposits are 
found in the presence of C3. 
The authors are indebted to Mr. Arthur H. Stewart for excellent technical assistance and to Dr. 
Eugene Wampler for first calling to our attention the relevance of Cox's work (22,24,25)  to our 
studies. 
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